{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:10:32Z","timestamp":1760346632992},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1097\/md.0000000000007534","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T20:23:08Z","timestamp":1505247788000},"page":"e7534","source":"Crossref","is-referenced-by-count":12,"title":["Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura"],"prefix":"10.1097","volume":"96","author":[{"given":"Emmanuelle","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quitterie","family":"Reynaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Fort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Durupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Cath\u00e9bras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Lega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210309","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports","volume":"85","author":"Terrell","year":"2010","journal-title":"Am J Hematol"},{"key":"R2-5-20210309","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s12325-011-0084-3","article-title":"Prevalence of diagnosed adult immune thrombocytopenia in the United Kingdom","volume":"28","author":"Bennett","year":"2011","journal-title":"Adv Ther"},{"key":"R3-5-20210309","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"R4-5-20210309","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"R5-5-20210309","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"key":"R6-5-20210309","first-page":"72","article-title":"Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases","volume":"90","author":"Vianelli","year":"2005","journal-title":"Haematologica"},{"key":"R7-5-20210309","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2004-12-4598","article-title":"How I treat idiopathic thrombocytopenic purpura (ITP)","volume":"106","author":"Cines","year":"2005","journal-title":"Blood"},{"key":"R8-5-20210309","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.amjmed.2003.12.024","article-title":"Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results","volume":"116","author":"Maloisel","year":"2004","journal-title":"Am J Med"},{"key":"R9-5-20210309","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.1990.tb02569.x","article-title":"Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases","volume":"74","author":"Quiquandon","year":"1990","journal-title":"Br J Haematol"},{"key":"R10-5-20210309","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"R11-5-20210309","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"R12-5-20210309","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R13-5-20210309","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R14-5-20210309","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R15-5-20210309","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2141.1991.tb04467.x","article-title":"Dapsone for idiopathic autoimmune thrombocytopenic purpura in elderly patients","volume":"78","author":"Durand","year":"1991","journal-title":"Br J Haematol"},{"key":"R16-5-20210309","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ajh.2830440117","article-title":"Dapsone for autoimmune thrombocytopenic purpura","volume":"44","author":"Godeau","year":"1993","journal-title":"Am J Hematol"},{"key":"R17-5-20210309","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ajh.2830460423","article-title":"Dapsone for idiopathic thrombocytopenic purpura","volume":"46","author":"Linares","year":"1994","journal-title":"Am J Hematol"},{"key":"R18-5-20210309","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2141.1995.tb05179.x","article-title":"Dapsone for refractory chronic idiopathic thrombocytopenic purpura","volume":"90","author":"Hern\u00e1ndez","year":"1995","journal-title":"Br J Haematol"},{"key":"R19-5-20210309","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2141.1999.01305.x","article-title":"Adult refractory chronic idiopathic thrombocytopenic purpura: can dapsone be proposed as second-line therapy?","volume":"104","author":"Radaelli","year":"1999","journal-title":"Br J Haematol"},{"key":"R20-5-20210309","first-page":"421","article-title":"Dapsone in treatment of chronic idiopathic thrombocytopenic purpura in adults","volume":"49","author":"Dutta","year":"2001","journal-title":"J Assoc Physicians India"},{"key":"R21-5-20210309","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ajh.22266","article-title":"Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab","volume":"87","author":"Zaja","year":"2012","journal-title":"Am J Hematol"},{"key":"R22-5-20210309","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.1989.tb00308.x","article-title":"Interferon alpha-2b therapy in adult chronic thrombocytopenic purpura (ITP)","volume":"73","author":"Bellucci","year":"1989","journal-title":"Br J Haematol"},{"key":"R23-5-20210309","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/0277-5379(91)90577-Z","article-title":"Alpha interferon therapy in the treatment of idiopathic thrombocytopenic purpura","volume":"27","author":"Proctor","year":"1991","journal-title":"Eur J Cancer Oxf Engl"},{"key":"R24-5-20210309","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1365-2141.1992.tb08157.x","article-title":"Recombinant alpha 2b interferon in the treatment of refractory autoimmune thrombocytopenic purpura","volume":"80","author":"Chistolini","year":"1992","journal-title":"Br J Haematol"},{"key":"R25-5-20210309","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-0609.1992.tb01806.x","article-title":"Recombinant alpha-2b interferon in refractory idiopathic immune thrombocytopenia","volume":"48","author":"Iannaccaro","year":"1992","journal-title":"Eur J Haematol"},{"key":"R26-5-20210309","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2169\/internalmedicine.31.1343","article-title":"Effect of interferon (IFN) on refractory idiopathic thrombocytopenic purpura: administration of 6 million units of recombinant IFN alpha-2b","volume":"31","author":"Ishii","year":"1992","journal-title":"Intern Med Tokyo Jpn"},{"key":"R27-5-20210309","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1365-2141.1992.tb06483.x","article-title":"Further concern over use of alpha-interferon in immune thrombocytopenic purpura","volume":"82","author":"Hudson","year":"1992","journal-title":"Br J Haematol"},{"key":"R28-5-20210309","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.1994.tb00651.x","article-title":"Interferon treatment of refractory idiopathic thrombocytopenic purpura (ITP)","volume":"52","author":"Dubbeld","year":"1994","journal-title":"Eur J Haematol"},{"key":"R29-5-20210309","first-page":"761","article-title":"Interferon-alpha 2b is not effective in the treatment of refractory immune thrombocytopenic purpura","volume":"83","author":"Vianelli","year":"1998","journal-title":"Haematologica"},{"key":"R30-5-20210309","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJM198306093082306","article-title":"Danazol for the treatment of idiopathic thrombocytopenic purpura","volume":"308","author":"Ahn","year":"1983","journal-title":"N Engl J Med"},{"key":"R31-5-20210309","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2141.1985.tb04070.x","article-title":"The use of danazol in the management of chronic immune thrombocytopenic purpura","volume":"61","author":"McVerry","year":"1985","journal-title":"Br J Haematol"},{"key":"R32-5-20210309","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000206176","article-title":"Danazol for the treatment of idiopathic thrombocytopenic purpura","volume":"74","author":"Buelli","year":"1985","journal-title":"Acta Haematol"},{"key":"R33-5-20210309","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000206184","article-title":"Danazol in idiopathic thrombocytopenic purpura","volume":"74","author":"Almagro","year":"1985","journal-title":"Acta Haematol"},{"key":"R34-5-20210309","first-page":"219","article-title":"Traitement du purpura thrombop\u00e9nique autoimmun chronique par danazol","volume":"18","author":"Fermand","year":"1985","journal-title":"Actual Hematol"},{"key":"R35-5-20210309","first-page":"275","article-title":"Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP)","volume":"28","author":"Ambr\u00edz","year":"1986","journal-title":"Nouv Rev Fr H\u00e9matologie"},{"key":"R36-5-20210309","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000205948","article-title":"Danazol therapy in refractory chronic immune thrombocytopenic purpura","volume":"77","author":"Mazzucconi","year":"1987","journal-title":"Acta Haematol"},{"key":"R37-5-20210309","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-107-2-177","article-title":"Low-dose danazol therapy in idiopathic thrombocytopenic purpura","volume":"107","author":"Ahn","year":"1987","journal-title":"Ann Intern Med"},{"key":"R38-5-20210309","first-page":"143","article-title":"The role of danazol in the treatment of refractory idiopathic thrombocytopenic purpura. A report of 22 cases","volume":"32","author":"Fenaux","year":"1990","journal-title":"Nouv Rev Fr H\u00e9matologie"},{"key":"R39-5-20210309","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/pgmj.66.780.827","article-title":"Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura","volume":"66","author":"Edelmann","year":"1990","journal-title":"Postgrad Med J"},{"key":"R40-5-20210309","first-page":"293","article-title":"Danazol therapy in idiopathic thrombocytopenic purpura: the efficacy of low-medium dose therapy","volume":"55","author":"Kondo","year":"1992","journal-title":"Int J Hematol"},{"key":"R41-5-20210309","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.23609","article-title":"Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies","volume":"89","author":"Khellaf","year":"2014","journal-title":"Am J Hematol"},{"key":"R42-5-20210309","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1046\/j.1365-2141.2002.03669.x","article-title":"Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults","volume":"118","author":"Provan","year":"2002","journal-title":"Br J Haematol"},{"key":"R45-5-20210309","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomized, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet"},{"key":"R46-5-20210309","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.revmed.2015.08.007","article-title":"Is there still a place for \u201cold therapies\u201d in the management of immune thrombocytopenia?","volume":"37","author":"Audia","year":"2016","journal-title":"Rev Med Int"},{"key":"R47-5-20210309","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/qjmed\/hcg050","article-title":"Danazol-induced hepatocellular carcinoma","volume":"96","author":"Confavreux","year":"2003","journal-title":"QJM"},{"key":"R48-5-20210309","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1067\/mva.2001.118078","article-title":"Danazol and limb-threatening arterial thrombosis: two case reports","volume":"34","author":"Alvarado","year":"2001","journal-title":"J Vasc Surg"},{"key":"R49-5-20210309","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N Engl J Med"},{"key":"R50-5-20210309","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJM200006223422506","article-title":"A comparison of observational studies and randomized, controlled trials","volume":"342","author":"Benson","year":"2000","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000007534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T22:14:31Z","timestamp":1719440071000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201709150-00005"}},"subtitle":["A PRISMA-compliant systematic review and meta-analysis of 28 studies"],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":48,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000007534","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}